The Dark Side of the Bright Side | GenomeWeb

Many pharmaceutical companies have been cutting their R&D budgets, and now, many biotechs are following suit, says Pharmalot's Ed Silverman. Even as biotech revenues are rising, companies are keeping hold of their cash and spending less on innovative research. "Overall, biotechs spent $54 million on R&D in 2010, which is down 7 percent from the previous year. This followed a 9 percent decline in spending in 2009," Silverman says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Insider Info

Gone Unreleased

Shuffled About

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.